Georgiamune Inc.

Today marks an important milestone for Georgiamune. We're proud to announce that the first cancer patient has been dosed with our GIM-531 drug. GIM-531 is a first-in-class, oral small-molecule cancer immunotherapy that selectively inhibits T regulatory cells. GIM-531 is designed to address indications and cancer types that are currently not addressed with existing or available immunotherapies.    This comes on the heels of GIM-122, a first-in-class dual-functioning antibody that's also already in clinical trials, treating cancer patients with high unmet needs. We're thrilled to now have two novel drugs in clinic less than a year from closing our Series A funding round. To learn more about GIM-531 and how Georgiamune is developing novel approaches to reach cancer and autoimmune disease patients around the world, visit: https://lnkd.in/gxpP_E7B #biotech #clinicaltrials #immunotherapies #cancer

We’re incredibly proud our CEO and Founder Samir Khleif was named a winner of the prestigious EY Entrepreneur of the Year Awards for his pioneering work and groundbreaking innovations in novel biology discoveries. Congratulations to the other finalists and winners!    To view all winners and learn more about the award, visit: https://go.ey.com/4eHrqW7 #EYEntrepreneurOfTheYear #EYAwards #EYEOY #novelbiology

Big news from our team today! We're excited to announce that GIM-531 has received IND clearance from the FDA. GIM-531 is a first-in-class oral treatment that selectively targets T-regulatory cells, while sparing other immune cells like CD4 and CD8. That's in addition to GIM-122, our first-in-class, dual-functioning antibody, which is in human clinical trials.    We're proud to help propel novel science, and are another step closer to reprogramming immune signaling pathways to redirect the immune system to fight cancer and autoimmune diseases. Learn more: https://lnkd.in/gjtA5pRP #clinicaltrials #FDAclearance #cancer #firstinclass #noveldrugs

Founder and CEO Samir Khleif sat down with RJ Lumba on the Great Entrepreneurs Podcast. Hear Dr. Khleif shed light on his background, the origin of Georgiamune and our mission to reprogram immune signaling pathways to redirect the immune system to fight diseases. https://lnkd.in/gu7UMzsn  #biotech #hiring 

Our CEO Samir Khleif sat down with Rebecca Torrence from Business Insider to share progress on GIM-122's clinical trial, our first-in-class pipeline, and our $75 million in Series A funding, co-led by General Catalyst and Parker Institute for Cancer Immunotherapy. Read the full article to learn how our novel biology is pioneering breakthroughs in cancer and autoimmune drugs: https://bit.ly/3vsRZMR #novelbiology #Georgiamune

A spotlight on Georgiamune's own Ramy Ibrahim, who is helping push the boundaries of novel discoveries as Chief Medical and Strategy Officer.    Dr. Ibrahim has more than two decades of drug development experience working in academia, major pharma companies, nonprofits, and everything in between. He's worked across a variety of therapeutic areas and has expertise with a wide scope of modalities. He's helped develop some of the first breakthrough treatments during his tenure at BMS, including the global approval of the first checkpoint inhibitor, Yervoy, and advancing the use of immunotherapy into the early stages of disease.   Want to join our team and work with experts like Dr. Ibrahim? https://lnkd.in/gWZKudT2 #hiring #novelbiology #Georgiamune

The American Association for Cancer Research recently published part 4 of a expert forecast exploring cutting-edge tech for oncology drug discovery. Learn how cutting-edge tech like #AI, chemical technology, and small-molecule chemical probes and tools, will continue to bring discoveries in research, drug discovery and therapeutics in 2024 and beyond.    To read the article, visit: https://bit.ly/49dKrfJ #oncology #drugdiscovery #chemicaltechnology

Are you passionate about the future of immunotherapy? Join our team of seasoned scientists to continue driving breakthroughs in novel biology. Take a look at current openings here: https://lnkd.in/g34HBfJJ #Georgiamune #NovelBiology 

Don’t forget to get your votes in for the Breakthrough BioTech Company of the Year on the annual BioBuzz Awards! We’re honored to be among this year’s list of innovative companies who are shaping the future of biotech with groundbreaking contributions. Vote for Georgiamune once a day through February 29, 2024 in the in the “BioHealth Capital Region Breakthrough Company of the Year Award” category: https://lnkd.in/em8UmZkh #BioBuzzAwards #BreakthroughCompany 

“Georgiamune works on discovering new and novel biology of T-cells, that are currently not existing, to affect our way of reprogramming those t-cells at the right time in the right position for a specific immunobiology needs of the micro environment” Our novel biology and drug discovery is propelling the fight towards reprogramming immune responses. Listen to our founder Samir Khleif as he shares his thoughts on New Horizons in oncology at the WuXi Global Forum: https://bit.ly/49gtlgy    #novelbiology #WuXiForum #NewHorizons